Back to top Open menu arrow
Download PDF Reprints

The Journal of
Clinical Psychiatry
Members only

Original Research Focus on Psychosis April 15, 2026

A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia

; ; ; ; ; ; ; ;

J Clin Psychiatry 2026;87(2):25m16022

Abstract

Objective: Cognitive impairment associated with schizophrenia (CIAS) is a key driver of functional deficits in patients with this disorder. CIAS may involve deficient NMDA receptor–dependent neurotransmission. Negative allosteric modulators (NAMs) of γ-aminobutyric acid (GABA) type A (GABAA) α5 receptors enhance their activity and improve cognition in rodents and nonhuman primates. We tested whether prolonged treatment with basmisanil—a selective GABAA α5 NAM—improved CIAS.

Methods: This 24-week placebo-controlled phase 2b study in patients with CIAS diagnosed according to DSM-5 was conducted between November 2016 and December 2019. Two hundred thirteen patients were randomized to 80 mg of basmisanil, 240 mg of basmisanil, or placebo twice a day. Recruitment into the 80 mg group was stopped after a planned futility analysis. The primary outcome was the MATRICS Consensus Cognitive Battery (MCCB) neurocognitive composite score evaluated in the efficacy analysis population (EAP) in the placebo (n=76) and basmisanil 240 mg arms only (n=77, total EAP n=153). Secondary outcome measures included specific hippocampal and prefrontal-dependent cognitive tasks, functional outcomes, and symptoms. Novel study design features addressing potential sources of heterogeneity in drug response and learning and practice effects included stratification by cognitive trajectories and age as well as repeated administration of the MCCB test battery during screening.

Results: Twenty-four weeks of treatment with basmisanil was well tolerated without improving cognitive or functional measures overall or in any of the stratified subgroups. Practice and learning effects were not observed at week 12.

Conclusion: Basmisanil did not improve cognitive deficits. Although unsuccessful, some results offer insight into important factors that should facilitate the design of more informative trials.

Trial Registration: ClinicalTrials.gov identifier: NCT02953639.

J Clin Psychiatry 2026;87(2):25m16022

Author affiliations are listed at the end of this article.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you're already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 1994;51(2):124–131. PubMed CrossRef
  2. Simon AE, Cattapan-Ludewig K, Zmilacher S, et al. Cognitive functioning in the schizophrenia prodrome. Schizophr Bull. 2007;33(3):761–771. PubMed CrossRef
  3. McCleery A, Nuechterlein KH. Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations. Dialogues Clin Neurosci. 2019;21(3):239–248. PubMed CrossRef
  4. McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023;28(5):1902–1918. CrossRef
  5. Keefe RS, Bilder RM, Harvey PD, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology. 2006;31(9):2033–2046. PubMed CrossRef
  6. Kharawala S, Hastedt C, Podhorna J, et al. The relationship between cognition and functioning in schizophrenia: a semi-systematic review. Schizophr Res Cogn. 2022;27:100217. CrossRef
  7. Bowie CR, Harvey PD. Cognitive deficits and functional outcome in schizophrenia. Neuropsychiatr Dis Treat. 2006;2(4):531–536. PubMed CrossRef
  8. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”. Schizophr Bull. 2000;26(1):119–136. PubMed CrossRef
  9. Bryson G, Bell MD. Initial and final work performance in schizophrenia: cognitive and symptom predictors. J Nerv Ment Dis. 2003;191(2):87–92. PubMed CrossRef
  10. Keefe RS, Buchanan RW, Marder SR, et al. Clinical trials of potential cognitive- enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013;39(2):417–435. PubMed CrossRef
  11. Talpos JC. Symptomatic thinking: the current state of Phase III and IV clinical trials for cognition in schizophrenia. Drug Discov Today. 2017;22(7):1017–1026. PubMed CrossRef
  12. Cotter J, Barnett JH, Granger K. The use of cognitive screening in pharmacotherapy trials for cognitive impairment associated with schizophrenia. Front Psychiatry. 2019;10:648. CrossRef
  13. Umbricht D, Vollenweider FX, Schmid L, et al. Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology. 2003 Jan;28(1):170–181. PubMed CrossRef
  14. Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res. 2003;140(1-2):1–47. PubMed CrossRef
  15. Gil-da-Costa R, Stoner GR, Fung R, et al. Nonhuman primate model of schizophrenia using a noninvasive EEG method. Proc Natl Acad Sci U S A. 2013;110(38):15425–15430. PubMed CrossRef
  16. McNally JM, McCarley RW, McKenna JT, et al. Complex receptor mediation of acute ketamine application on in vitro gamma oscillations in mouse prefrontal cortex: modeling gamma band oscillation abnormalities in schizophrenia. Neuroscience. 2011;199:51–63. PubMed CrossRef
  17. Nakamura T, Dinh TH, Asai M, et al. Suppressive effects of ketamine on auditory steady-state responses in intact, awake macaques: a non-human primate model of schizophrenia. Brain Res Bull. 2023;193:84–94. CrossRef
  18. Cadinu D, Grayson B, Podda G, et al. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. 2018;142:41–62. PubMed CrossRef
  19. Javitt DC, Zukin SR, Heresco-Levy U, et al. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr Bull. 2012;38(5):958–966. PubMed CrossRef
  20. Umbricht D, Schmid L, Koller R, et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000;57(12):1139–1147. PubMed CrossRef
  21. Rosburg T, Kreitschmann-Andermahr I. The effects of ketamine on the mismatch negativity (MMN) in humans: a meta-analysis. Clin Neurophysiol. 2016;127(2):1387–1394. PubMed CrossRef
  22. Schuelert N, Dorner-Ciossek C, Brendel M, et al. A comprehensive analysis of auditory event-related potentials and network oscillations in an NMDA receptor antagonist mouse model using a novel wireless recording technology. Physiol Rep. 2018;6(16):e13782. PubMed CrossRef
  23. Singh T, Poterba T, Curtis D, et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022;604(7906):509–516. CrossRef
  24. Rudolph U, Möhler H. GABAA receptor subtypes: therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol. 2014;54:483–507. PubMed CrossRef
  25. Crestani F, Keist R, Fritschy JM, et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8980–8985. PubMed CrossRef
  26. Collinson N, Kuenzi FM, Jarolimek W, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABAA receptor. J Neurosci. 2002;22(13):5572–5580. PubMed CrossRef
  27. Yee BK, Hauser J, Dolgov VV, et al. GABA receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur J Neurosci. 2004;20(7):1928–1936. PubMed CrossRef
  28. Hipp JF, Knoflach F, Comley R, et al. Basmisanil, a highly selective GABAA- alpha5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man. Sci Rep. 2021;11(1):7700.
  29. Redrobe JP, Elster L, Frederiksen K, et al. Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats. Psychopharmacology. 2012;221(3):451–468. PubMed CrossRef
  30. Sur C, Fresu L, Howell O, et al. Autoradiographic localization of alpha5 subunit- containing GABAA receptors in rat brain. Brain Res. 1999;822(1-2):265–270. 31. PubMed CrossRef
  31. Myers JF, Comley RA, Gunn RN. Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans. J Cerebr Blood Flow Metabol. 2017;37(6):2137–2148. PubMed CrossRef
  32. Goeldner C, Kishnani PS, Skotko BG, et al. A randomized, double-blind, placebo- controlled phase II trial to explore the effects of a GABAA-alpha5 NAM (basmisanil) on intellectual disability associated with Down syndrome. J Neurodev Disord. 2022;14(1):10.
  33. Weickert TW, Goldberg TE, Gold JM, et al. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry. 2000;57(9):907–913. PubMed CrossRef
  34. Carruthers SP, Van Rheenen TE, Karantonis JA, et al. Characterising demographic, clinical and functional features of cognitive subgroups in schizophrenia spectrum disorders: a systematic review. Neuropsychol Rev. 2022;32(4):807–827. CrossRef
  35. Dickinson D, Zaidman SR, Giangrande EJ, et al. Distinct polygenic score profiles in schizophrenia subgroups with different trajectories of cognitive development. Am J Psychiatry. 2020;177(4):298–307. CrossRef
  36. Weinberg D, Lenroot R, Jacomb I, et al. Cognitive subtypes of schizophrenia characterized by differential brain volumetric reductions and cognitive decline. JAMA Psychiatry. 2016;73(12):1251–1259. CrossRef
  37. Jastak S. WRAT-R: Wide Range Achievement Test. New and revised edition. Jastak Associates, Inc; Stoelting Co;1984.
  38. Wechsler D. Wechsler Abbreviated Scale of Intelligence. The Psychological Corporation;1999.
  39. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. AmJ Psychiatry. 2008;165(2):203–213. PubMed CrossRef
  40. August SM, Kiwanuka JN, McMahon RP, et al. The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates. Schizophrenia Res. 2012;134(1):76–82. PubMed CrossRef
  41. Drozdick LW, Raiford SE, Wahlstrom D, et al. The Wechsler Adult Intelligence Scale—Fourth Edition and the Wechsler Memory Scale—Fourth Edition. In: Contemporary Intellectual Assessment: Theories, Tests, and Issues. 4th ed. The Guilford Press;2018:486–511.
  42. Tombaugh TN. Trail making test A and B: normative data stratified by age and education. Archives Clin Neuropsychology. 2004;19(2):203–214. PubMed CrossRef
  43. Morosini P, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329. PubMed
  44. Keefe RSE, Davis VG, Spagnola NB, et al. Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. Eur Neuropsychopharmacol. 2015;25(2):176–184. PubMed CrossRef
  45. Guy W. ECDEU assessment manual for psychopharmacology. In: Rev., US Dept of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration. National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs;1976.
  46. Keefe RSE, Davis VG, Atkins AS, et al. Validation of a computerized test of functional capacity. Schizophr Res. 2016;175(1-3):90–96. CrossRef
  47. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. CrossRef
  48. Kirkpatrick B, Strauss GP, Nguyen L, et al. The Brief Negative Symptom Scale: psychometric properties. Schizophr Bull. 2011 Mar;37(2):300–305. CrossRef
  49. Mohn C, Sundet K, Rund BR. The relationship between IQ and performance on the MATRICS Consensus Cognitive Battery. Schizophr Res Cognition 2014. 2014;1(2):96–100. CrossRef
  50. Keefe RS, Fox KH, Harvey PD, et al. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011;125(2-3):161–168. PubMed CrossRef
  51. Keefe RSE, Davis VG, Harvey PD, et al. Placebo response and practice effects in schizophrenia cognition trials. JAMA Psychiatry. 2017;74(8):807–814. CrossRef
  52. Roediger HL, Karpicke JD. Test-enhanced learning: taking memory tests improves long-term retention. Psychol Sci. 2006;17(3):249–255. PubMed CrossRef
  53. Roediger HL 3rd, Karpicke JD. The power of testing memory: basic research and implications for educational practice. Perspect Psychol Sci. 2006;1(3):181–210. CrossRef
  54. Larsen DP, Butler AC, Roediger HL 3rd. Repeated testing improves long-term retention relative to repeated study: a randomised controlled trial. Med Educ. 2009;43(12):1174–1181. PubMed CrossRef
  55. Rowland CA. The effect of testing versus restudy on retention: a meta-analytic review of the testing effect. Psychol Bull. 2014;140(6):1432–1463. PubMed CrossRef
  56. Elliott R, McKenna PJ, Robbins TW, et al. Specific neuropsychological deficits in schizophrenic patients with preserved intellectual function. Cogn Neuropsychiatry. 1998:3(1):45–69. CrossRef
  57. Kremen WS, Seidman LJ, Faraone SV, et al. Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers. Biol Psychiatry. 2001;50(6):453–462. PubMed CrossRef

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

Cover features March 2026 issue highlighting articles on psychiatric drugs, peer interventions for perinatal depression, and metformin.

Vol 87 • 2026 • Number 1

Read the Current Issue

Original Research

Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024

Meta-Analysis

Effectiveness of Peer-Administered Interventions for Perinatal Depression or Anxiety

Original Research

Effect of Adjuvant Metformin on Adherence to and Persistence of Treatment With SGAs in Nondiabetic Patients

Editorial

Thank You to the JCP Community

Editorial

Psychotherapy: Integral to Clinical Psychiatry

Original Research

Trends in Benzodiazepine Prescribing to Adults in the United States
View current Issue

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe